Incidence of Symptomatic and Asymptomatic Bacteriuria After Urodynamic Study in Women

Sponsor
Federal University of São Paulo (Other)
Overall Status
Completed
CT.gov ID
NCT03106103
Collaborator
(none)
217
69.9

Study Details

Study Description

Brief Summary

Urodynamic Study (UDS) represents a series of agreed-upon clinical tests and is used to evaluate the functional status of the lower urinary tract, providing a pathophysiological basis for urinary symptoms. Urodynamic Study involves catheterization of the lower urinary tract. The prevalence of urinary tract infection after UDS ranges from 1,5% to 30 %.

Studies of prophylactic antibiotics for UDSs have offered data of contradictory and limited predictive values. Some investigators concluded that prophylactic antibiotics were valuable and others have not.

The objective of this study is to evaluate the efficacy of antibiotic prophylaxis before UDS in women, using different antibiotic regimens.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study is randomized, double blind study was carried out in the Department of Gynecology at Sao Paulo Federal University from January 2009 to December 2012.

    The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin. The tablets were administered 30 minutes before de UDS.

    All patients were instructed to collect midstream urine sample to the microbiology laboratory 14 days after the UDS. Significant bacteriuria was considered when >1.000.000 organisms/mL of a single species was isolated.

    All data were entered into Statistical Package for Social Sciences (SPSS) 16.0 for statistical analysis and graphic representation. Likelihood -ratio test and Fisher's exact test were used to compare the prevalence of significant bacteriuria after UDS in the different groups and Student's t-test and ANOVA test were used to compare continuous variables. To compare the groups regarding the BMI variable and parity, the model analysis of variance (ANOVA) was used, or if necessary, the nonparametric Kruskal-Wallis test and to compare the groups in relation to menopause variable, we used the Chi-square test. A significance level of 0.05 was established for statistical analysis.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    217 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Incidence of Symptomatic and Asymptomatic Bacteriuria After Urodynamic Study With or Without Antibiotic Prophylaxis in Women With Urinary Incontinence
    Study Start Date :
    Feb 1, 2009
    Actual Primary Completion Date :
    Dec 1, 2012
    Actual Study Completion Date :
    Dec 1, 2014

    Arms and Interventions

    Arm Intervention/Treatment
    Women with urinary incontinence

    The patients were randomized in four groups: Group A received 500mg of levofloxacin, group B received placebo, group C received 80mg trimethoprim and 400mg sulfamethoxazole (SMZ-TMP) and group D received 100mg of nitrofurantoin.

    Outcome Measures

    Primary Outcome Measures

    1. Incidence of symptomatic and asymptomatic bacteriuria after urodynamic study in women with urinary incontinence [24 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 82 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    • Inclusion Criteria: Women with 20 to 85 years old, clinical diagnosis of urinary incontinence with indication for urodynamic study, absence of genital prolapse or prolapse peak effort that does not exceed the hymen, absence of urinary tract infection

    • Exclusion Criteria: Patients with diabetes mellitus, history of recurrence urinary tract infection, with genital prolapse that exceed de hymen, pregnant, kidney stone, allergy to antibiotics, use of urethral catheters delay

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Federal University of São Paulo

    Investigators

    • Principal Investigator: Elizabeth Hirakauva, Doctor, Federal University of São Paulo

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Elizabeth Yukie Hirakauva, doctor, Federal University of São Paulo
    ClinicalTrials.gov Identifier:
    NCT03106103
    Other Study ID Numbers:
    • EYH-2014
    First Posted:
    Apr 10, 2017
    Last Update Posted:
    Apr 10, 2017
    Last Verified:
    Apr 1, 2017
    Keywords provided by Elizabeth Yukie Hirakauva, doctor, Federal University of São Paulo
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 10, 2017